In addition, a meta-analysis evaluating 27 trials has confirmed the effectiveness of tocilizumab, where use of this anti-IL-6 antibody decreased 28-day all-cause mortality in patients hospitalized for COVID-19 [219]. Here, IL6 is linked to COVID-19.